Evaluation of S100B, NSE, MBP and GFAP serum levels in children with attention deficit hyperactivity disorder

Öz

Purpose: This study aimed to investigate serum levels of S100B protein, Neuron Specific Enolase (NSE), Myelin Basic Protein (MBP) and Glial Fibrillary Acidic Protein (GFAP) that reflect glial and neural structure. To date, these proteins have been studied in neuropsychiatric diseases and relation with neuronal damage has been shown. However, there is no study that simultaneously evaluates the serum levels of these proteins in children with ADHD and compares them with healthy controls. Materials and methods: 44 children with ADHD and 37 healthy volunteers participated in the study. They were selected from children and adolescents aged 6-18 years who had no history of other medical or psychiatric diseases and had not used psychotropic drugs for the last six months. Levels of proteins were assessed by enzyme-linked immunosorbent assay (ELISA). Results: Serum levels of S100B, NSE and GFAP were found to be statistically significantly higher in the ADHD group than in the control group (p=0.012, p=0.000, p=0.001, respectively). No significant difference was found in the intergroup comparison for MBP (p=0.181). Conclusion: Increased levels of S100B, NSE, GFAP may be an indicator of neuronal or glial changes in ADHD. Future studies combining serial measurements of these biochemical proteins with genetics and neuroimaging data are needed to evaluate the possible role of glial and neuronal damage in the etiopathogenesis of ADHD.

Anahtar Kelimeler

• ADHD
• glia
• astrocyte
• neuroinflammation

Destekleyen Kurum

This study was supported by Pamukkale University Scientific Research Projects Commission with the decision numbered 2018TIPF038.

Proje Numarası

PAÜ BAP 2018TIPF038

Etik Beyan

Pamukkale University Non-Interventional Clinical Research Ethics Committee in the meeting dated 29.05.2018 and numbered 11, with the number 601167787-020/40438

Teşekkür

The study authors would like to thank Pamukkale University Scientific Research Projects Commission

Dikkat eksikliği hiperaktivite bozukluğu olan çocuklarda serum S100B, NSE, MBP ve GFAP düzeylerinin değerlendirilmesi

Öz

Amaç: Bu çalışmanın amacı glial ve nöral yapıyı yansıtan S100B proteini, Nöron Spesifik Enolaz (NSE), Miyelin Bazik Protein (MBP) ve Glial Fibriller Asidik Protein (GFAP) serum düzeylerini araştırmaktır. Bugüne kadar bu proteinler nöropsikiyatrik hastalıklarda çalışılmış ve nöronal hasarla ilişkisi gösterilmiştir. Ancak bu proteinlerin serum düzeylerini DEHB'li çocuklarda eş zamanlı olarak değerlendirerek sağlıklı kontroller ile karşılaştıran bir çalışma mevcut değildir. Gereç ve yöntem: Çalışmaya 44 DEHB’li ve 37 sağlıklı gönüllü katımıştır. Katılımcılar, başka tıbbi veya psikiyatrik hastalık öyküsü olmayan ve son altı aydır psikotropik ilaç kullanmayan 6-18 yaş arası çocuk ve gençler arasından seçilmiştir. Serum protein seviyeleri enzim-bağlı immünosorbent yöntemi (ELISA) ile değerlendirilmiştir. Bulgular: S100B, NSE ve GFAP serum düzeyleri, DEHB grubunda kontrol grubundan istatistiksel olarak anlamlı düzeyde yüksek bulunmuştur (sırasıyla p=0,012, p=0,000, p=0,001). MBP için gruplar arası karşılaştırmada anlamlılık düzeyinde bir farklılık saptanmamıştır (p=0,181). Sonuç: S100B, NSE, GFAP'nin yükselmiş düzeyleri DEHB'deki nöronal veya glial değişikliklerin bir göstergesi olabilir. DEHB etiyopatogenezinde glial ve nöronal hasarın olası rolünü değerlendirmek için bu biyokimyasal proteinlerin seri ölçümlerini genetik ve nörogörüntüleme verileriyle birleştiren gelecek çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

• DEHB
• glia
• astrosit
• nöroinflamasyon

Destekleyen Kurum

PAÜ BAP

Proje Numarası

PAÜ BAP 2018TIPF038

Etik Beyan

601167787-020/40438 numara ile etik kurul onayı alınmıştır.

Teşekkür

Pamukkale Üniversitesi BAP'a teşekkürlerimizle.

Kaynakça

1. 1. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57(11):1215-1220. doi:10.1016/j.biopsych.2004.10.020
2. 2. Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1:15020. Published 2015 Aug 6. doi:10.1038/nrdp.2015.20
3. 3. Polanczyk GV, Casella EB, Miguel EC, Reed UC. Attention deficit disorder/hyperactivity: a scientific overview. Clinics (Sao Paulo). 2012;67(10):1125-1126. doi:10.6061/clinics/2012(10)01
4. 4. Faraone SV, Bonvicini C, Scassellati C. Biomarkers in the diagnosis of ADHD--promising directions. Curr Psychiatry Rep. 2014;16(11):497. doi:10.1007/s11920-014-0497-1
5. 5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95. doi:10.1067/mcp.2001.113989
6. 6. Mehta T, Mannem N, Yarasi NK, Pradeep C, Bollu PC. Biomarkers for ADHD: the Present and Future Directions. Curr Dev Disord Rep. 2020;7:85-92. doi:10.1007/s40474-020-00196-9
7. 7. Lamers KJ, Vos P, Verbeek MM, Rosmalen F, van Geel WJ, van Engelen BG. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull. 2003;61(3):261-264. doi:10.1016/s0361-9230(03)00089-3
8. 8. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003;60(6):540-551. doi:10.1002/jemt.10296

9. 9. Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain?. J Neurosci Res. 2007;85(7):1373-1380. doi:10.1002/jnr.21211
10. 10. Park ES, Park CI, Choi KS, Choi IH, Shin JS. Over-expression of S100B protein in children with cerebral palsy or delayed development. Brain Dev. 2004;26(3):190-196. doi:10.1016/S0387-7604(03)00126-8
11. 11. Manev H, Manev R. S100B: an old neurotrophic factor with putative new roles in psychiatric illnesses. J Psychiatr Res. 2001;35(6):347-350. doi:10.1016/s0022-3956(01)00039-5
12. 12. Al Ayadhi LY, Mostafa GA. A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children. J Neuroinflammation. 2012;9:54. Published 2012 Mar 16. doi:10.1186/1742-2094-9-54
13. 13. Shaker NM, Taha GR, Kholeif H, Sayed NM, El Sheikh MM, Abulmagd ML. Serum levels of S100b, interleukin-6 and anti-transglutaminase Ii IgA as immune markers in a sample of egyptian children with autistic spectrum disorders. Autism Open Access. 2016;6:1-8. doi:10.4172/2165-7890.1000191
14. 14. Smith TF, Anastopoulos AD, Garrett ME, et al. Angiogenic, neurotrophic, and inflammatory system SNPs moderate the association between birth weight and ADHD symptom severity. Am J Med Genet B Neuropsychiatr Genet. 2014;165B(8):691-704. doi:10.1002/ajmg.b.32275
15. 15. Oades RD. An exploration of the associations of pregnancy and perinatal features with cytokines and tryptophan/kynurenine metabolism in children with attention-deficit hyperactivity disorder (ADHD). Atten Defic Hyperact Disord. 2011;3(4):301-318. doi:10.1007/s12402-011-0062-2
16. 16. Liu W, Huo X, Liu D, Zeng X, Zhang Y, Xu X. S100β in heavy metal-related child attention-deficit hyperactivity disorder in an informal e-waste recycling area. Neurotoxicology. 2014;45:185-191. doi:10.1016/j.neuro.2014.10.013
17. 17. Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci. 1987;10:269-295. doi:10.1146/annurev.ne.10.030187.001413
18. 18. Kawata K, Liu CY, Merkel SF, Ramirez SH, Tierney RT, Langford D. Blood biomarkers for brain injury: What are we measuring?. Neurosci Biobehav Rev. 2016;68:460-473. doi:10.1016/j.neubiorev.2016.05.009
19. 19. Isgrò MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:125-143. doi:10.1007/978-94-017-7215-0_9
20. 20. Wiener CD, Jansen K, Ghisleni G, et al. Reduced serum levels of neuron specific enolase (NSE) in drug-naïve subjects with major depression and bipolar disorder. Neurochem Res. 2013;38(7):1394-1398. doi:10.1007/s11064-013-1036-x
21. 21. Stancioiu F, Bogdan R, Dumitrescu R. Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD). Life (Basel). 2023;13(8):1736. Published 2023 Aug 13. doi:10.3390/life13081736
22. 22. Ayaydın H, Kirmit A, Çelik H, Akaltun İ, Koyuncu İ, Bilgen Ulgar Ş. High Serum Levels of Serum 100 Beta Protein, Neuron-specific Enolase, Tau, Active Caspase-3, M30 and M65 in Children with Autism Spectrum Disorders. Clin Psychopharmacol Neurosci. 2020;18(2):270-278. doi:10.9758/cpn.2020.18.2.270
23. 23. Esnafoglu E, Ayyıldız SN, Cırrık S, et al. Evaluation of serum Neuron-specific enolase, S100B, myelin basic protein and glial fibrilliary acidic protein as brain specific proteins in children with autism spectrum disorder. Int J Dev Neurosci. 2017;61:86-91. doi:10.1016/j.ijdevneu.2017.06.011
24. 24. Demirci E, Tastepe N, Gul MK, Ozmen S, Kilic E. S100B and Neuron-Specific Enolase Levels as Brain Injury Biomarkers in Internet Addiction: Effect of Sleep. Pediatr Neurol. 2023;149:93-99. doi:10.1016/j.pediatrneurol.2023.08.029
25. 25. Whitaker JN. Myelin basic protein in cerebrospinal fluid and other body fluids. Mult Scler. 1998;4(1):16-21. doi:10.1177/135245859800400105
26. 26. Petzold A. The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up. J Neurol Neurosurg Psychiatry. 2015;86(12):1388-1390. doi:10.1136/jnnp-2014-309827
27. 27. Ahlsén G, Rosengren L, Belfrage M, et al. Glial fibrillary acidic protein in the cerebrospinal fluid of children with autism and other neuropsychiatric disorders. Biol Psychiatry. 1993;33(10):734-743. doi:10.1016/0006-3223(93)90124-v
28. 28. Cetin I, Bulut H, Simsek S. Examination of the Neuroplastic Biomarker Levels in Attention Deficit Hyperactivity Disorder. Asian J Biochem. 2017;12:1-8. doi:10.3923/ajb.2017.1.8
29. 29. Turgay A. Disruptive behavior disorders: child and adolescent screening and rating scales for children, adolescents, parents and teachers. West Bloomfield (Michigan): Integrative Therapy Institute Publication; 1994.
30. 30. Ercan ES, Amado S, Somer O, Çıkoğlu S. Development of a test battery for the assessment of attention deficit hyperactivity disorder. Turkish J of Child and Adolesc Mental Health. 2001;8:132-144.
31. 31. Grant DA, Berg EA. Wisconsin Card Sorting Test [Database record]. APA PsycTests. 1948. doi:10.1037/t31298-000
32. 32. Heaton RK. A manual for the Wisconsin Card Sorting Test. Odessa, FL: Psychological Assessment Resources;1981.
33. 33. Karakaş S. BİLNOT Bataryası El Kitabı: Nöropsikolojik Testler için Araştırma ve Geliştirme Çalışmaları (1. Ed.). Ankara: Dizayn Ofset;2004.
34. 34. Stroop, J. R. (1935). Studies of interference in serial verbal reactions. Journal of experimental psychology, 1935;18(6):643-662. doi:0.1037/h0054651
35. 35. Kilic G, İlden Kockar A, Irak M, Şener S, Karakaş S. The standardizatıon study of the stroop test TBAG form in chıldren between 6-11 years of age. Turkish J of Child and Adolesc Mental Health. 2002;9(2):86-99.
36. 36. Janigro D, Mondello S, Posti JP, Unden J. GFAP and S100B: What You Always Wanted to Know and Never Dared to Ask. Front Neurol. 2022;13:835597. Published 2022 Mar 21. doi:10.3389/fneur.2022.835597
37. 37. Kozlowski T, Bargiel W, Grabarczyk M, Skibinska M. Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review. Brain Sci. 2023;13(9):1334. Published 2023 Sep 16. doi:10.3390/brainsci13091334
38. 38. Oades RD, Dauvermann MR, Schimmelmann BG, Schwarz MJ, Myint AM. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism--effects of medication. Behav Brain Funct. 2010;6:32. Published 2010 Jun 9. doi:10.1186/1744-9081-6-32.
39. 39. Ouadih Moran M, Muñoz Hoyos A, D'Marco L, Molina Carballo A, Seiquer I, Checa Ros A. Is S100B Involved in Attention-Deficit/Hyperactivity Disorder (ADHD)? Comparisons with Controls and Changes Following a Triple Therapy Containing Methylphenidate, Melatonin and ω-3 PUFAs. Nutrients. 2023;15(3):712. Published 2023 Jan 31. doi:10.3390/nu15030712
40. 40. Royds JA, Timperley WR, Taylor CB. Levels of enolase and other enzymes in the cerebrospinal fluid as indices of pathological change. J Neurol Neurosurg Psychiatry. 1981;44(12):1129-1135. doi:10.1136/jnnp.44.12.1129
41. 41. Wilkinson AA, Dennis M, Simic N, et al. Brain biomarkers and pre-injury cognition are associated with long-term cognitive outcome in children with traumatic brain injury. BMC Pediatr. 2017;17(1):173. Published 2017 Jul 24. doi:10.1186/s12887-017-0925-6
42. 42. Lv MN, Zhang H, Shu Y, Chen S, Hu YY, Zhou M. The neonatal levels of TSB, NSE and CK-BB in autism spectrum disorder from Southern China. Transl Neurosci. 2016;7(1):6-11. Published 2016 Feb 18. doi:10.1515/tnsci-2016-0002
43. 43. Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015;32:121-130. doi:10.1016/j.ceb.2015.02.004
44. 44. Heimfarth L, Passos FRS, Monteiro BS, Araújo AAS, Quintans Júnior LJ, Quintans JSS. Serum glial fibrillary acidic protein is a body fluid biomarker: A valuable prognostic for neurological disease - A systematic review. Int Immunopharmacol. 2022;107:108624. doi:10.1016/j.intimp.2022.108624
45. 45. Stevens HE, Scuderi S, Collica SC, Tomasi S, Horvath TL, Vaccarino FM. Neonatal loss of FGFR2 in astroglial cells affects locomotion, sociability, working memory, and glia-neuron interactions in mice. Transl Psychiatry. 2023;13(1):89. Published 2023 Mar 11. doi:10.1038/s41398-023-02372-y
46. 46. Lim SY, Mah W. Abnormal Astrocytosis in the Basal Ganglia Pathway of Git1(-/-) Mice. Mol Cells. 2015;38(6):540-547. doi:10.14348/molcells.2015.0041
47. 47. Nowak MK, Ejima K, Quinn PD, et al. ADHD May Associate With Reduced Tolerance to Acute Subconcussive Head Impacts: A Pilot Case-Control Intervention Study. J Atten Disord. 2022;26(1):125-139. doi:10.1177/1087054720969977
48. 48. Chen L, Hu X, Ouyang L, et al. A systematic review and meta-analysis of tract-based spatial statistics studies regarding attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2016;68:838-847. doi:10.1016/j.neubiorev.2016.07.022
49. 49. Shaw P, Sudre G, Wharton A, Weingart D, Sharp W, Sarlls J. White matter microstructure and the variable adult outcome of childhood attention deficit hyperactivity disorder. Neuropsychopharmacology. 2015;40(3):746-754. doi:10.1038/npp.2014.241
50. 50. Tezcan ME, Ekici F, Ugur C, et al. Do specific myelin autoantibodies and increased cerebral dopamine neurotrophic factor in the context of inflammation predict the diagnosis of attention deficit hyperactivity disorder in medication-free children?. Brain Behav Immun. 2025;124:125-136. doi:10.1016/j.bbi.2024.11.026